Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Ketamine, a dissociative anesthetic and psychedelic compound, has revolutionized the field of psychopharmacology by showing robust, and rapid-acting antidepressant activity in patients suffering from major depressive disorder (MDD), suicidal tendencies, and treatment-resistant depression (TRD). Ketamine’s efficacy, however, is transient, and patients must return to the clinic for repeated treatment as they experience relapse. This is cause for concern because ketamine is known for its abuse liability, and repeated exposure to drugs of abuse often leads to drug abuse/dependence. Though the mechanism(s) underlying its antidepressant activity is an area of current intense research, both clinical and preclinical evidence shows that ketamine’s effects are mediated, at least in part, by molecular adaptations resulting in long-lasting synaptic changes in mesolimbic brain regions known to regulate natural and drug reward. This review outlines our limited knowledge of ketamine’s neurobiological and biochemical underpinnings mediating its antidepressant effects and correlates them to its abuse potential. Depression and addiction share overlapping neural circuitry and molecular mechanisms, and though speculative, repeated use of ketamine for the treatment of depression could lead to the development of substance use disorder/addiction, and thus should be tempered with caution. There is much that remains to be known about the long-term effects of ketamine, and our lack of understanding of neurobiological mechanisms underlying its antidepressant effects is a clear limiting factor that needs to be addressed systematically before using repeated ketamine in the treatment of depressed patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698 · cited 5×
“Several studies have demonstrated its role in controlling the firing of VTA DA neurons [77].”
BackgroundInfluentialmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059 · cited 3×
“In models of drug addiction, the NAc has been shown to be involved in drug reward prediction, drug-taking behavior, and cue-elicited drug seeking and reinstatement [73,129].”
BackgroundBlockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 4×
“indicating that synaptic activity may be required for the release of BDNF and the subsequent antidepressant effects of ketamine [3].”
BackgroundInfluentialThe brain reward circuitry in mood disorders
Russo, S. J., & Nestler, E. J. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3381 · Cited by 1,870 · cited 1×
“Increases in BDNF expression have also been associated with increased drug cravings [146].”
BackgroundKetamine—its pharmacology and therapeutic uses
white, P. F., Way, W. L., & Trevor, A. J. (1982) · Anesthesiology · doi:10.1097/00000542-198202000-00007 · Cited by 1,474
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
The brain on drugs: from reward to addiction
Volkow, N. D., & Morales, M. (2015) · Cell · doi:10.1016/j.cell.2015.07.046 · Cited by 1,306
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“) of ketamine, over a 40 minute duration, significantly reduced depressive symptoms when compared to saline or midazolam placebo controls [8,122,196].”
BackgroundMayberg, H. S. (2003) · British Medical Bulletin · doi:10.1093/bmb/65.1.193 · Cited by 1,166
Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons
Chaudhury, D., Walsh, J. J., Friedman, A. K., Juarez, B., Ku, S. M., Koo, J. W., Ferguson, D., Tsai, H.-C., Pomeranz, L., Christoffel, D. J., et al. (2013) · Nature · doi:10.1038/nature11713 · Cited by 1,156
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 2×
“Levels of GSK-3β have been reported to be significantly increased in depressed patients, and ketamine treatment has been shown to increase the phosphorylation of this protein [9,88,194].”
BackgroundMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Ketamine blocks bursting in the lateral habenula to rapidly relieve depression
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018) · Nature · doi:10.1038/nature25509 · Cited by 1,036
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“Subsequent studies have also demonstrated ketamine’s efficacy in reducing suicidal ideation [32].”
BackgroundThe circuitry mediating cocaine-induced reinstatement of drug-seeking behavior
McFarland, K., & Kalivas, P. W. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08655.2001 · Cited by 905
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“However, other in vitro studies have indicated that ketamine may enhance GABAA receptor mediated inhibition [67,123].”
BackgroundFunctional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 1×
“Although ketamine’s antidepressant effects in some clinical settings had been observed since the 1970’s (reviewed in 26), a link between glutamate and depression was first reported by Trullas and Skolnick nearly 25 years ago: They demonstrated that competitive, channel-blocking and glycine-site NMDA receptor antagonis…”
BackgroundKetamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711 · cited 3×
“5) aqueous solution containing benzothonium chloride or chlorbutanol as preservative [113].”
BackgroundInfluentialSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Synaptic potentiation onto habenula neurons in the learned helplessness model of depression
Li, B., Piriz, J., Mirrione, M., Chung, C., Proulx, C. D., Schulz, D., Henn, F., & Malinow, R. (2011) · Nature · doi:10.1038/nature09742 · Cited by 634 · cited 1×
“Increased activation of neurons projecting from the lateral habenula to the VTA has been observed in mice expressing depressive phenotypes following exposure to the learned helplessness and the chronic social defeat paradigms [19,85].”
BackgroundLong-lasting Hyperalgesia Induced by Fentanyl in Rats: Preventive Effect of Ketamine
Célèrier, E., Rivat, C., Jun, Y., Laulin, J.-P., Larcher, A., Reynier, P., & Simonnet, G. (2000) · Anesthesiology · doi:10.1097/00000542-200002000-00029 · Cited by 584
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Kapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459
Untangling the complexity of opioid receptor function
Valentino, R. J., & Volkow, N. D. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0225-3 · Cited by 383
Morgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02761.x · Cited by 373
Miller, O. H., Yang, L., Wang, C.-C., Hargroder, E. A., Zhang, Y., Delpire, E., & Hall, B. J. (2014) · eLife · doi:10.7554/elife.03581 · Cited by 358
Koike, H., Iijima, M., & Chaki, S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.035 · Cited by 346 · cited 1×
“2011 [75] Male ICR mice (25– 35 g) Single dose of 3–30 mg/kg i.”
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335 · cited 1×
“However, the recent discovery of its rapid-acting antidepressant effects in patients who typically do not respond to traditional antidepressant therapy has brought this drug renewed limelight [61].”
BackgroundMaes, M., Fišar, Z., Medina, M., Scapagnini, G., Nowak, G., & Berk, M. (2012) · Inflammopharmacology · doi:10.1007/s10787-011-0111-7 · Cited by 325
Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
Beurel, E., Song, L., & Jope, R. S. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.47 · Cited by 288
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Browne, C. A., & Lucki, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00161 · Cited by 285
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
Liu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256
Sex differences in the antidepressant-like effects of ketamine
Carrier, N., & Kabbaj, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.12.009 · Cited by 251
Duman, R. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/rduman · Cited by 249
The role of the brain reward system in depression
Naranjo, C. A., Tremblay, L. K., & Busto, U. E. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00156-7 · Cited by 245 · cited 1×
“This is due to this circuit’s role in the control of motivation and hedonic value under normal conditions, and alterations in reward and motivational processes play a central role in the manifestation of core symptoms of both MDD and drug addiction [44,77,125,129,185].”
BackgroundThe molecular and cellular mechanisms of depression: a focus on reward circuitry
Fox, M. E., & Lobo, M. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0415-3 · Cited by 232 · cited 3×
“This is due to this circuit’s role in the control of motivation and hedonic value under normal conditions, and alterations in reward and motivational processes play a central role in the manifestation of core symptoms of both MDD and drug addiction [44,77,125,129,185].”
BackgroundGideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232 · cited 1×
“2014 [54] Male C57BL/6 mice (6–8 weeks) Single dose of 3 mg/kg i.”
Belujon, P., & Grace, A. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.014 · Cited by 225 · cited 24×
“For example, optogenetic stimulation of VTA-NAc DA projecting neurons, but not VTA-mPFC DA projecting neurons, induced social withdrawal and anhedonia (i.e., depression-like behaviors) after exposure to subthreshold social defeat stress, while inhibition of both projections reversed these effects [20].”
BackgroundInfluentialHare, B. D., Shinohara, R., Liu, R. J., Pothula, S., DiLeone, R. J., & Duman, R. S. (2019) · Nature Communications · doi:10.1038/s41467-018-08168-9 · Cited by 217 · cited 1×
“2019 [60] Male and female C57BL/6 mice Single dose of 10 mg/kg i.”
BackgroundLaje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213 · cited 1×
“Depressed patients carrying this mutated BDNF allele also show decreased response to ketamine’s antidepressant effects [83].”
BackgroundNeuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201
The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine
Monteggia, L. M., Gideons, E., & Kavalali, E. T. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.006 · Cited by 198 · cited 2×
“Ketamine causes the inhibition of eEF2K, which induces an increase in phosphorylated eEF2 (p-eEF2), and a resultant increase in BDNF translation and protein synthesis [114].”
BackgroundChowdhury, G. M. I., Zhang, J., Thomas, M., Banasr, M., Ma, X., Pittman, B., Bristow, L., Schaeffer, E., Duman, R. S., Rothman, D. L., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.34 · Cited by 197
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism
Gigliucci, V., O’Dowd, G., Casey, S., Egan, D., Gibney, S., & Harkin, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3024-x · Cited by 177
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174
Yang, C., Hu, Y.-M., Zhou, Z.-Q., Zhang, G.-F., & Yang, J.-J. (2013) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.724118 · Cited by 173 · cited 1×
“2013 [191] Male Wistar rats (180–220 g) Single dose of 10 mg/kg i.”
Donahue, R. J., Muschamp, J. W., Russo, S. J., Nestler, E. J., & Carlezon, W. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.014 · Cited by 161 · cited 1×
“Donahue et al. 2014 [35] Male C57BL/6 mice (6–8 weeks) Single dose of 2.5 or 20 mg/kg i.p. Increased social interaction score 24 h post treatment in animals treated with 20 mg/kg ketamine dose.”
MethodInfluentialSanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
Turner, E. H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30394-3 · Cited by 156
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148 · cited 1×
“synaptic activity of mesocorticolimbic regions [77,78,171].”
mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse
Neasta, J., Barak, S., Hamida, S. B., & Ron, D. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12725 · Cited by 114
A Word to the Wise About Intranasal Esketamine
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19040423 · Cited by 96 · cited 2×
“The use of ketamine for the treatment of depression has raised serious concerns across the field, ranging from the scarcity of data on efficacy and safety, to its potential for misuse [52,151,168].”
BackgroundPal, H. R., Berry, N., Kumar, R., & Ray, R. (2002) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0203000323 · Cited by 87
Gong, L., Yin, Y., He, C., Ye, Q., Bai, F., Yuan, Y., Zhang, H., Lv, L., Zhang, H., Xie, C., et al. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.016 · Cited by 82 · cited 1×
“These deficits in network connectivity are significantly associated with cognitive deficits (including learning and memory) and depression severity in depressed patients [56].”
BackgroundA case of ketamine dependence with discontinuation symptoms
Critchlow, D. G. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01494.x · Cited by 79
Jett, J. D., Boley, A. M., Girotti, M., Shah, A., Lodge, D. J., & Morilak, D. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3957-3 · Cited by 75
Noble, F., & Marie, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00742 · Cited by 56 · cited 1×
“The effects presented in these studies might be a case of drug substitution [132].”
Background(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.5.779a · Cited by 49
Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
Rasmussen, K. G. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.002 · Cited by 32
WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?: Editorial
Newport, D. J., Schatzberg, A. F., & Nemeroff, C. B. (2016) · Depression and Anxiety · doi:10.1002/da.22535 · Cited by 30
Cited by
Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073759 · Cited by 425
Kryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00097-z · Cited by 159
Antianhedonic effect of repeated ketamine infusions in patients with treatment resistant depression
Wilkowska, A., Wiglusz, M. S., Gałuszko-Wegielnik, M., Włodarczyk, A., & Cubała, W. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.704330 · Cited by 35
“Dysregulation of the reward system function has been described in depression, anhedonia, but also in addictions (28).”
Background
Metadata
- Authors
- Kokane, S. S., Armant, R. J., Bolaños-Guzmán, C. A., & Perrotti, L. I.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 384
- Pages
- 112548
- ISSN
- 0166-4328 (ISSN-L)
- OpenAlex
- W3005582604
- Cited by
- 61
- References
- 69
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.